The work carried ou as part of Phase IIb stage of development of EMI-137 has showed FME using EMI-137 appeared to be safe andfeasible within a 1- to 3-h dose-to-imaging interval. No clinicallysignificant differences were observed among the cohorts, althougha 1-h dose-to-imaging interval was...
To accelerate evelopment of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – 17 December 2019 – Edinburgh Molecular Imaging Ltd, a company developing theragnostic agents targeting cancer, today announces the closing of a...
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom - 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment of Dr Bernhard Sixt as Chief Executive Officer, effective immediately....
EDINBURGH, Scotland, October 29, 2018 - Roy Davis appointed as Non-Executive Chairman - Current Chair John Jeans to continue as Non-Executive Director Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces the...
Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner. EM Imaging, based in Edinburgh, is partnering with Bowel Cancer UK and Beating Bowel Cancer to raise funds for the charity and increase awareness of Scotland’s second biggest cancer killer....
Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK – 19 September 2017: Edinburgh Molecular Imaging (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces it has commenced a pivotal Phase...
Edinburgh Molecular Imaging is proud to support the University of Edinburgh team.The researchers aim to create new chemicals – known as tracers – to illuminate these unstable plaques in patients. The tracers – which contain small amounts of radioactivity – are injected into the bloodstream and...
The EM Imaging team hosted Paul Wheelhouse MSP, Minister for Business, Innovation and Energy at our laboratories and offices at Edinburgh Bioquarter. We took the opportunity to explain the value of being based near world leading clinicians who can help us drive our products through clinical...
Our CEO Ian Wilson will be at the Biotech Showcase on January 9–11 in San Francisco. Contact him through the partnering system to arrange a meeting.
OBN Awards 2016 Winners Recognised at Industry Leading EventEM Imaging CEO Ian Wilson celebrates wining the Best Emerging Medtech Company Award at OBN 2016. At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company Award. The...